Omeprazole versus famotidine in the short-term treatment of duodenal ulcer disease.
The efficacy and safety of omeprazole, in 241 patients with active recurrent duodenal ulcer from 21 Italian centres, was studied in a multicentre double-blind randomized trial comparing 20 mg omeprazole o.m. or 40 mg famotidine nocte with endoscopic examination, symptom recording, laboratory screening and gastrin assay. In a per protocol analysis, the duodenal ulcer healing rates for omeprazole and famotidine, documented by endoscopy, were 62% (68/109) and 33% (39/117) after 2 weeks of treatment (P less than 0.001), 92% (96/104) and 80% (86/108) cumulative after 4 weeks (P less than 0.05), and 99% (102/103) and 92% (96/104) after 6 weeks (P less than 0.05), respectively. The results of this trial demonstrate that 20 mg omeprazole o.m. is superior to 40 mg famotidine nocte in duodenal ulcer healing.
Delle Fave
G
G
Cattedra di Gastroenterologia I, La Sapienza University, Rome, Italy.
Annibale
B
B
Franceschi
M
M
Quatrini
M
M
Cassetta
M R
MR
Torsoli
A
A
D015746:Abdominal Pain / Q000188:drug therapy / Q000209:etiology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004381:Duodenal Ulcer / Q000150:complications / Q000188:drug therapy*; D005069:Evaluation Studies as Topic; D015738:Famotidine / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005755:Gastrins / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000009:adverse effects / Q000627:therapeutic use*
D005755:Gastrins; D015738:Famotidine; D009853:Omeprazole